An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Antiandrogens; Gallium (68Ga) gozetotide
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PSMAddition
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 19 Sep 2024 Status changed from active, no longer recruiting to recruiting.
- 21 Nov 2023 Planned primary completion date changed from 28 Aug 2024 to 23 Jul 2025.
- 15 Nov 2023 Planned primary completion date changed from 23 Jul 2025 to 28 Aug 2024.